Remove

Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date			10797298
			2004-03-09
First Named Inventor Mark		Mark	D. Elkovitch
	Art Unit		1754
Examiner Name Chi H		Chi H	I. Pham
	Attorney Docket Numb	er	134380-2

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	of cited Document Silvi et al.		Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1	6107415		2000-08-22					
	2	6388046		2002-05-14					
	3	6936233 B2		2005-08-30	Smalley et al.	Smalley et al.			
If you wisi	h to a	d additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	ICATION PUB	LICATIONS		Remove	
Examiner Cite Initial* No Publication Number		Kind Code ¹	Publication Date		Name of Patentee or Applicant Rei		Columns,Lines whe ant Passages or Rele s Appear		
	1	20030213939	A1	2003-11-20	Narayan et al.				
	2	20050070657		2005-03-31	Elkovitch et a	Elkovitch et al.			
If you wis	h to a	dd additional U.S. Publis	shed Ap	plication citat	on information	please click the Ad	d button	Add	
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner	Cite		Country Code ²		Publication e4 Date	Name of Patente Applicant of cited	e or	Pages,Columns,Line where Relevant Passages or Relevan	TS

U.S.PATENTS

	1								
If you wis	h to a	dd add	ditional Foreign	Patent Documer	t citation	information pl	ease click the Add buttor	Add	
				NON-PATI	NT LIT	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(e), volume-issue number(e), publisher, city andorc country where publisher.								T6
	1								
If you wis	h to a	dd add	ditional non-pat	tent literature doc	ument ci	tation informat	on please click the Add I	outton Add	
EXAMINER SIGNATURE									
Examiner	Signa	ture					Date Considered		
*EXAMIN	ER: Ir	itial if	reference cons	sidered, whether	or not cit	ation is in conf	ormance with MPEP 609	Draw line through a	

See Kind Codes of USPTO Patent Documents at view.USPTO.QDV or MPEP 901.04. * Enter office that issued the document, by the Noveletor (WIPO Standard ST3.). * For Laplanese patent document, the antication of the year of the region for the Emperor warp precess the sent annument patent document. * And of coursent by the spropriate symbols as enducated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if Empirish targuages transitions in statched.*

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10797298
Filing Date		2004-03-09
First Named Inventor Mark		D. Elkovitch
Art Unit		1754
Examiner Name	Chi H	l. Pham
Attorney Docket Numb	er	134380-2

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.	97 and 1.	98 to make the	e appropriate	selection(s):
---------------	----------	-----------	----------------	---------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

-					
Signature	/David E. Rodrigues/	Date (YYYY-MM-DD)	2006-08-18		
Name/Print	David E. Rodrigues	Registration Number	50604		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.